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Abstract 
Postoperative nausea and vomiting (PONV) and postdischarge nausea and vomiting 
(PDNV) continue to be a serious problem in the ambulatory setting.  These symptoms are  
among  the most undesired complications following surgery and can adversely affect the 
quality of recovery for many patients. Previous research has concluded that the 
identification of risk factors for PONV/PDNV is a first step in developing effective 
prevention strategies.  The purpose of this study was to examine the incidence of PONV/ 
PDNV in the ambulatory setting in female clients who were treated with transdermal 
scopolamine (TDS) for motion sickness as compared to those patients who were not 
treated with TDS. The study design was a two-group retrospective chart review.  Of the 
group identified with a positive history and not treated with TDS, 54% (n=6) developed 
PONV /PDNV as compared to 26% (n=3) that were treated. This pilot study provided 
preliminary support that preoperative identification of PONV/PDNV risk factors and 
treatment with TDS reduces PONV/PDNV.  Standardized, comprehensive risk factor 
identification in the preoperative period is indicated.   
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Prevention and Management of Postoperative Nausea and Vomiting in Ambulatory 
Surgery: How Well Are We Identifying Patients with Motion Sickness? 
 
Background / Statement of Problem 
Postoperative nausea and vomiting (PONV) is a serious problem in the ambulatory 
surgical setting. Identified as a surgical problem since 1848, after the introduction of 
anesthesia, PONV is one of the most undesired complications following surgery.1 One 
third of all patients requiring anesthesia for surgery will develop PONV, and as many as 
30% to 50% of outpatients will develop postdischarge nausea and vomiting (PDNV) after 
their arrival home.2   From 1996 to 2006, the number of outpatient surgery visits in the 
United States (US) increased from 20.8 to 34.7 million, accounting for half of all 
surgeries .3 With the increasing number of outpatients surgeries,  PDNV will also 
increase, making the identification of risk factors and preventing PONV and PDNV an 
important factor in the saftey and satisfaction of these patients. 
 
PONV encompasses three main symptoms, nausea, vomiting and retching, which may 
occur separately or in combination after surgery.4 Each vomiting episode delays 
discharge from recovery room by 25 minutes.5 It is estimated that approximately 0.2% of 
all surgical patients  may experience intractable PONV, leading to delays in discharge 
from recovery areas and unanticipated hospital admissions following ambulatory 
surgery.6 
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A history of motion sickness or prior PONV are considered independent predictors for 
PONV, likely because the patient has already established a reflex arc for vomiting.7  
Motion sickness is a syndrome that occurs in response to a real or perceived motion.8 
Early assessment and treatment of patients at risk for PONV before surgery, including 
those with a history of motion sickness, can minimize negative outcomes. The purpose of 
this study was to examine the incidence of PONV/ PDNV in the ambulatory setting in 
female clients treated with transdermal scopolamine for motion sickness as compared to 
those patients who are not treated with scopolamine. 
  
 Literature Review 
The processes of nausea, vomiting, and retching are coordinated by the vomiting center 
in the brain.9 Nausea is a subjective and unpleasent sensation that is associated with the 
urge to vomit. Vomiting and retching are objective patient experiences; vomiting 
(emesis) includes the forceful expulsion of gastric contents from the mouth, and retching 
represents an unproductive effort to vomit.10 Stimulation of these processes can be 
initated from the periphery and centrally from the CNS. Stimuli are relayed from the 
periphery to the vomiting centre by the autonomic nervous system afferent neurons of the 
vagus nerve. There is afferent input to the area postrema from the vagal and 
glossopharyngeal nerves. Central cerebral sensory stimuli occur directly and are 
transmitted by the chemoreceptor trigger zone (CTZ) area postrema, and nucleus of the 
solitary tract in the lateral reticular formation of the medulla to the vomiting centre. 
Chemicals in the CSF and blood have a direct stimulating effect at the vomiting centre.9 
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The areas in the CNS associated with balance, vasomotor activity, salivation, respiration 
and bulbar control are located near, and have innervations to, the vomiting centre. The 
close proximity of these areas to the vomiting centre corresponds to the physiological 
reactions seen in PONV, such as tachypnea, tachycardia, sweating, increased swallowing, 
cardiac dysrhythmias, and motion sickness. 9 
 
Postoperative nausea and vomiting occur after 25% to 30% of surgeries and significantly 
contribute to patients’ discomfort, distress, and dissatisfaction .9 Among high-risk 
patients, the incidence of PONV can be as high as 70%.11 The most common of 
postsurgical complications, PONV and PDNV affect approximately 25 million patients 
worldwide yearly with an estimated financial impact of several million dollars.12,13  The 
incidence of PDNV is more difficult to document due to lack of reporting, but it has been 
estimated that one-third of patients will experience PDNV after discharge from 
ambulatory setting.2 With more than 60% to 65% of surgeries performed in an 
ambulatory setting, PDNV is a significant problem affecting thousands of patients .2 Until 
recently, there has been no clear definition of PDNV, although the term is related to 
discharge of a patient after ambulatory surgery. A strategic work team, convened by 
American Society of PeriAnesthesia Nurses (ASPAN), distinguished PDNV from PONV.  
PDNV was defined as nausea or vomiting that occurs after discharge from a surgical 
facility, while PONV was identified as occurring within the first 24 hours of surgery.14 
The question as to whether the person who is nauseated or has emesis during transport 
home is diagnosed with PONV or PDNV remains. 15 
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Despite the use of prophylactic antiemetics for preventing PONV, many surgical patients 
undergoing general anesthesia still experience PONV in the post anesthesia care unit, the 
hospital, and at home after discharge.16 ASPAN developed practice guidelines designed 
to assist the practitioner to identify high-risk patients and develop a multimodal plan of 
treatment; risk factors were identified as surgery related, anesthesia related, and patient 
related.14  Surgery  related factors that increase risk include type of surgery, length of 
surgery, and anesthesia techniques used. Surgeries that have a direct relationship on 
increased incidence of PONV include eye, oral, plastic, ear, nose and throst, head and 
neck, gynecological, obstetric, laproscopic and abdominal procedures.17 Longer 
operations (greater than three hours) allow for longer exposure to lipid soluble, 
potentially emetic intravenous, and inhalation gas anesthetics, all of which can cause an 
increase in PONV.18 
  
Compared with a purely regional anesthetic technigue, general anesthesia is associated 
with a significantly higher incidence of nausea, vomiting, and overall PONV.19  This fact 
raises the question as to the contribution of the drugs used during surgery. There have 
been several meta-analysis that have shown decreased nausea and vomiting when 
propofol is used as opposed to inhalation agents. 20,21,22 Some anesthetic agents increase 
the risk of PONV. Apfel and colleagues conducted a large clinical trial of 5199 patients.  
Each patient had at least a 40% risk of PONV according to a simplfied risk score, based 
on the presence of at least two risk factors. This trial simultaneously evaluated  
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antiemetic efficacy and anesthetic interventions. All the tested antiemetics appeared 
similarily effective; substituting propofol for a volatile anesthetic reduced the rate of 
PONV by 19%, whereas substituting nitrogen for nitrous oxide reduced the risk by 12%. 
Combining these two anesthetic strategies ( total intravenous anesthesia) reduced the risk 
by as much as any single antiemetic. In a  trial comparing nitrous oxide group with an 
oxgen enriched air group, Myles et al.23 found that the group receiving nitrious oxide had  
significantly more severe adverse events, including pulmonary complications, wound 
infections, and fever; the oxgen enriched air group had lower rates of severe nausea and 
vomiting.   
 
Patient specific risk factors for PONV/ PDNV include female gender, non-smoking 
status, and the use of opioids for postoperative analgesia, motion sickness, or previous 
PONV.10,16, 24  Nonsmokers are at higher risk of development of PONV than smokers.7 
Chatterjee et al. 6 identified that  chronic exposure to smoke, in particular polycyclic 
aronmatic hydrocarbons, produced changes in liver microsomal enzymes that may 
change the metabolism of drugs used in the peri-operative period and the capicity of these 
drugs to produce PONV.6 There is a three fold increase in the incidence of PONV in 
patients who have a history of PONV or motion sickness.4 A history of motion sickness 
or prior PONV/PDNV are considered independent predictors of PONV.7 
 
Motion sickness is a syndrome that occurs in response to real or perceived motion, and 
includes gastrointestinal, central nervous system, and autonomic symptoms.8 Motion 
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sickness occurs following stimulation of the vestibular apparatus of the inner ear; 
following this stimulation, transmission of impulse to the CTZ and vomiting centre 
occurs, relaying to the CNS the sensation of nausea and motion sickness. Vomiting may 
then occur. Characteristics that show some correlation to motion sickness are sex, age, 
hormonal factors, disease that alter vestibular or visual sensory cues, and migraine .8 
Physical signs of motion sickness include sense of dizziness, nausea, belching, increased 
salavation, warmth, and diaphoresis, along with a feeling of malaise.8 In two independent 
investigations, Cheung et al. 25 found no effect of  menstrual cycle on motion sickness, 
whereas Golding et al. 26  found an increased susceptibility to motion sickness.,27 
Accurate assessment of motion sickness and effective treatment are key.  
      
Knowledge of risk factors is essential for the identification of high-risk patients and 
effective multimodal management of PONV.28 Several risk assessment tools have been 
developed using multiple regression analysis to identify factors that are strong 
independent predictors of PONV.28  Palazzo and Evans, 29 Koivuranta et al.,30 and Apfel 
et al.24 each developed risk assessment tools.  Each tool  included the same five variables 
in the risk score, including female gender, nonsmoking status, history of PONV, history 
of motion sickness, and postoperative use of opioids .28 The Apfel model has been 
successfully used to predict which patients are likley to develop PONV.12 On the basis of 
the Apfel et al.12 risk scoring system, a female patient who has had a history of PONV 
and is receiving opioids for pain has a 60% chance of developing PONV.31 
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It is recommended that any risk model must undergo external validation before it can be 
used in clinical practice.10 Given the limitations in validating PONV risk factors, it is not 
surprising that scoring systems have shown only poor to moderate accuracy. Despite the 
limitations, their use to better tailor antimetic interventions has been shown to 
significantly reduce the incidence of PONV particularly in high risk patient populations.10  
The prediction of PONV/PDNV relies  on the assessment of the patient, and places 
emphasis on how well the evaluation is completed.  In a review done by Eberhart & 
Morin, risk score assessment was found to be  a useful tool to predict PONV,  though 
anaesthesiologists tend not too use them.32 Criticism of the general application of  PONV 
scores is based not only on the systematic lack of external validation of the scores but 
also on other methodological issues.32 
 
Clinical practice guidelines for managing PONV and PDNV have been developed by the 
American Society of Anesthesiologists (ASA),33 the American Society of Perianesthesia 
Nurses (ASPAN),14 and the Society of Ambulatory Anesthesia (SAMBA).13 ASA 
guidelines provide an evidence-based reference tool for anesthesia providers in the 
management of patients at risk for PONV/PDNV.33 The ASA guidelines include: risk 
factor identification for PONV using the simplified Apfel et al.24 risk factor assessment 
tool;  recommendations to reduce the baseline risk for PONV and identify the optimal 
approach to PONV prevention and therapy; guidelines to determine the choice and timing 
of antiemetic administration; and identify the most effective monotherapy and 
combination therapy.33  
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Antiemetic medications are the most common treatment for PONV.  Because there is no 
single receptor or stimulus for PONV, no one amtiemetic will be effective in all 
patients.31 In 2007, SAMBA revised ASA guidelines and made  recommendations for 
treating PONV/PDNV to include transdermal scopolamine (TDS) as one of the first and 
second line antiemetic for use in motion sickness.12 In 2001, the US Food and Drug 
Administration approved the use of transdermal scopolamine (TDS) for the prevention of 
PONV. TDS is a long acting prophylactic antiemetic initially developed to prevent 
motion sickness; it is a centrally acting anticholinergic agent.34 Scopolamine is an 
effective preoperative antiemetic; it crosses the blood brain barrier and blocks cholinergic 
stimulation of the vomiting center from both the gastrointestinal tract and the vestibular 
center. TDS has been shown to be associated with significant reductions in PONV with 
both early and late patch application during the first 24 hours after the start of 
anesthesia.34 Anesthesia departments play a key role in promoting the adherence to 
guidelines by monitoring the incidence of PONV and  instituting policies that align with  
current recommendations. 35 
 
ASPAN organized an Evidence Based Practice Strategic Work Team (SWT) consisting 
of 16 multi-disciplinary, multi-specialty experts to review published evidence related to 
the prevention and/or management of PONV/PDNV. The guidelines apply to both 
inpatient and outpatient settings and to procedures performed in the operating room, as 
well as in other locations where sedation and anesthesia may be given.14 
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Recommendations included prophylactic treatment of PONV based on the patients’ level 
of risk, determined by risk factor assessment. Simplified risk factor tools establish the 
patients’ baseline risk for PONV, and the number of interventions based on the level of 
risk. 12ASPAN included the simplified risk factors tools  as developed by Apfel et al.24 
and Koivuranta et al.30 to establish the patient’s baseline risk for developing PONV. 14 
Prophylactic recommendations include anesthesia related (total intravenous anesthesia 
TIVA), pharmacologic therapeutic (hydration, and pain management), and 
complementary interventions (acupoint). 14 In addition to pharmacologic agents 
recommened by ASA, PONV prophylaxis, H1 receptor blockers (antihistamines) and the 
scopolamine patch were recommend in the case of patients with motion sickness. 14 
 
Conceptual Model 
The Symptom Management model was used to guide this research; the model was 
developed in 1994, by the University of California, San Francisco (UCSF) Symptom 
Management Team and revised in 2001 to include broad based symptom management.36 
A symptom is a subjective experience, reflected in the bio-psychosocial functioning, 
sensations, or cognition of an individual,36 as compared to a sign, which is defined as any 
abnormality indicative of disease that is detectable by the individual or by others. 36 The 
UCSF model includes signs when needed to assess disease status and to evaluate and 
verify the effectiveness of management strategies. 36 The Symptom Management Model 
is based on the premise that effective management of any given symptom or group of 
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symptoms demands that all three dimensions be considered: the interrelatedness of the 
symptom experience; symptom management strategies; and outcomes.   
 
The revised model recognizes the domains of nursing science, person, health/illness and 
environment, which influence the three dimensions. The symptom experience includes an 
individual’s perception of the symptom, evaluation of the meaning of the symptom, and 
response to a symptom. The goal of symptom management is to avert negative outcomes, 
and begins in the assessment phase of the symptom experience, followed by identifying 
and focusing on intervention strategies. Interventions are targeted at one or more 
components of the individual’s symptom experience to achieve desired outcomes.36 
Although the physiology of the vomiting center is understood; the pathways to control 
nausea and vomiting are not well defined.36 
 
Method 
The purpose  of this study was to examine the incidence of  PONV/PDNV in the 
ambulatory setting in female clients who were treated with TDS for motion sickness as 
compared to those who were not treated with TDS. 
Research Design 
The study was designed as a two-group retrospective chart review; the groups included a 
convenience sample of 156 female clients. Group 1 included those female clients who 
were identified as  having a previous history of PONV/PDNV or motion sickness and 
were treated with TDS; Group 2 included females with a history of motion sickness who 
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were not treated with TDS. The hypothesis was that patients identified with a previous 
history and/or motion sickness and treated with TDS  preoperatively would have a 
decreased rate of PONV/PDNV, as opposed to those who were not treated with TDS. 
Site  
This study was conducted at The Fain Health Center, an ambulatory surgical unit at The 
Miriam Hospital, Providence R.I. The Fain Health Center provides care to clients 
undergoing ambulatory surgery.  
Sample  
Inclusion criteria included those female clients 17 years or older who had received 
general anesthesia for laproscopic, gynecological, or breast surgery and had been  
identified as having a history of PONV/PDNV or motion sickness , either through 
preoperative nursing assessment or through anesthesia assessment, and were either  
treated with TDS or not treated with TDS. Exclusion criteria included those who met 
inclusion critera but had received emetrogenic or antiemetic drugs within the 24 hours 
prior to surgery, as well as clients for whom  TDS was contraindicated. 
Procedures 
Prior to data collection, permission was obtained from the Lifespan and Rhode Island 
College Institutional Review Boards (IRB). Institutional permission was also obtained 
from the Director of Surgical Services. After approval, the student investigator obtained a 
list of clients from the surgical schedule whose surgeries occurred between  January  and  
October 2012. The list was submitted to health information services via a medical record 
request form, and requested records were retrieved by the health information staff.  Once 
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retrieved, the student investigator  reviewed records for  the identified inclusion/ 
exclusion criteria.   
The student investigator  extracted relevant data, using a data collection tool developed 
from the literature review and clinical experience  (Appendix A). The focus of the tool 
was on risk factors for PONV/PDNV as well as anti-emetics used and use of TDS.  
Documentation reviewed included the preadmission assessment form, anesthesia 
assessment form, and the pre-procedure verfication form. 
 Data Analysis 
Descriptive statistic techniques were used to summarize findings.  Differences between 
groups related to PONV/PDNV were examined. 
 
Results 
A total of 180 records were reviewed; 24 were not included because those clients  had  
received modified anesthesia as compared to general anesthesia. Prophylactic antiemetics 
administered  to all clients intraoperatively included dexamethasone 4mg (Decadron) and 
ondansetron  4mg (Zofran).   Data from  remaining records (n=156) were then further 
examined to identify those in which a history of PONV/PDNV or motion sickness was 
identified, typically during the preadmission interview or when interviwed by the 
anesthesiologist the day of surgery. A total of 26 clients (17%) were identified as having 
a history of PONV/PDNV or motion sickness. The characteristics of the 26 clients are 
illustrated in Table 1.  
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Table 1 
Risk Characteristics of Clients Identified with PONV/PDNV or Motion Sickness 
Total Clients 
Identified with 
PONV/PDNV or 
Motion Sickness 
 
(n = 26; 16.6%) 
  
Treated with 
TDS 
 
n =15  (58 %) 
 
Not 
Treated with 
TDS 
n =11 (42%) 
 
Smoking Status 
Never        
Former         
Current        
 
n=  22 (85%) 
n=3 (11%) 
n=1 (5%) 
 
n= 15 (100%) 
n =0 
n =0 
 
n = 7 (73%) 
n = 3 (18%) 
n = 1 (9%) 
Type of surgery  
Laproscopic       
Breast                
Gynecological      
 
n=12 (46%) 
n=13 (50%) 
n=1 (4%) 
 
n = 6 (40%) 
n = 8 (53%) 
n =1 (7%) 
 
n = 6 (55%) 
n = 5 (45%) 
n = 0  
 
The age range of clients was from 17 to 75 with a mean of 44.2 years. The majority of the 
sample were non smokers  (n=22; 85%) and half had undergone breast procedures (n = 
13). 
 
The remaining 130 medical records (83%) included no documentation as to whether there 
was a history of PONV/PDNV or motion sickness. None of these forms have a specific 
area for documentation of risk factors, and only the preadmission  form had a question 
asking if the client or family members had any difficulty with anesthesia. The client 
recruitment breakdown is illustrated in Figure 1.  
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Figure 1. Distrubution of PONV/PDNV  
 
Twenty six clients (17%) identified having a history of PONV/PDNV or motion sickness.  
Of those 26, 15 (58%) were treated with TDS, while 11 (42%) were not treated. Of those 
that were  treated with TDS  (n =15), 26% (n= 3) developed PONV/PDNV as compared 
to those with a history of PONV/ PDNV or motion sickness (n =11)  and not treated  
(n=6; 54%). In the group without documentation related to whether a history of 
PONV/PDNV or motion sickness existed (n=130), 48 ( 37%) developed PONV/PDNV.  
 
Discussion  
The purpose of this study was to examine the incidence of PONV/ PDNV in the 
ambulatory setting in female clients who were treated with TDS  for motion sickness as 
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  developed	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compared to those clients who were not treated with TDS.  PONV/PDNV continues to be 
a significant problem despite the use of antiemetics and negatively affect patients’ quality 
of recovery and patient satisfaction. In this study, when a history of PONV/ PDNV or 
motion sickness was identified and treated with TDS, PONV/ PDNV were reduced as 
compared to when not treated with TDS (26% versus 54% respectively).  
 
Guidelines have been developed by ASA, 33 ASPAN, 14 and SAMBA 13 to assist 
clinicians with an evidence-based, practical approach to the prevention and/ or 
management of PONV and PDNV. These guidelines were developed to serve as a 
resource to anesthesia providers and perianesthesia nurses involved in the care of patients 
at risk for PONV/ PDNV.14 Although these guidelines serve as a tool for the management 
of PONV, they also suggest that not all patients will benefit from antiemetic prophylaxis, 
and that the identification of patients who are at increased risk leads to the most effective 
use of therapy.4   This study provided supportive evidence that preoperative identification 
of risk factors and treatment with TDS can potentially reduce PONV/PDNV.  
 
Limitations 
 Given that this was a retrospective design, the information retrieved from records was 
limited to what was documented. Results of the study may have been affected by certain 
variables that were not controlled for including the use of volatile anesthetics, and 
postoperative use and administration of opioids. This study was limited by a small sample 
size and the limited amount of demographic data that was collected. 
 
 
 
                                                                                                                     
                                                                                                                                    16 
Recommendations for Practice 
Nausea and vomiting are commonly feared by surgical patients, and remain the source of 
significant anxiety for patients and families. PONV/PDNV also has the potential to 
negatively impact patient outcomes, and can result in increased length of stay for the 
patient and the institution. Prevention of PONV/PDNV is a high priority for nurses in the 
perianesthesia setting; when prevention is not possible, effective treatment is the primary 
goal.  Reliable and valid risk assessment tools are available for use in clinical settings, 
and recommended for use by ASA and ASPAN. Consistent use of a risk assessment tool 
to identify risk factors for PONV/PDNV before surgery is recommended.  
  
Conclusions 
In spite of the advances made in anesthesia and in management of post-operative 
symptoms, PONV/ PDNV continue to be a problem for surgical patients. Kapur referred 
to PONV as the “big little problem”.37 Identification of high-risk patients is essential to 
the prevention of PONV/PDNV. The Symptom Management Model guided this research 
and is based on the assumption that the symptom does not have to be experienced by an 
individual for the individual to be at risk for the development of the symptom. 36 It is 
easier to treat nausea and prevent vomiting than to stop vomiting once it has started.1 
Collaboration and communication of risk factors between the anesthesia team and 
nursing staff members must occur in order to bring best practices to the patient. Accurate 
identification of PONV/PDNV risk factors in the interdisciplinary treatment plan is an 
essential first step; perianesthesia nurses are positioned to obtain an accurate assessment 
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of patient risk for PONV/ PDNV. The integration of a Clinical Nurse Specialist (CNS) to 
the perianesthesia team would assist the nurses in problem identification, critique, and 
review of the literature, as well as in the design and implementation of practice changes 
to improve patient outcomes. The CNS is trained to work within and across the patient, 
nursing, and systems /organizational spheres, and plays a major role in impacting policy. 
The CNS needs to work to assure that existing guidelines and policies related to 
prevention of PONV / PDNV are implemented and continuously evaluated. The 
reduction of PONV/ PDNV rates through the use of standardized risk factor assessment 
tool can positivity increase patient satisfaction and improve patient outcomes. National 
adoption will better assure that clinical prevention and population health objectives are 
met. 
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Appendix A 
Researcher-Developed Data Collection Tool 
	  
PONV= Postoperative Nausea and Vomiting; PDNV= Post Discharge Nausea and 
Vomiting; GYN= Gynecological 
. 
Age	   Race	   Smoking	  
History	  
History	  
of	  
PONV	  
History	  
of	  
Motion	  
Sickness	  
Anesthesia	  
Type	  
	  
Type	  of	  Surgical	  Procedure	  
Number	  of	  
Antiemetic	  
Use	  of	  	  
Scopolamine	  
PONV	   PDNV	  
Laparoscopic	   Breast	   GYN	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